MCM6 and meningioma: The aim of this study was to evaluate the prognostic value of MCM6 relative to that of Ki-67 in a series of grade 1 (World Health Organization 2021; n = 100) and grade 2 (atypical) meningiomas (n = 69), using immunohistochemistry, and to evaluate its correlation with methylation classes.